Table 2.
Characteristic | Total (N=1014) | Total PCMC score | ||
---|---|---|---|---|
Low (n=251) | Medium (n=485) | High (n=278) | ||
Dignity and respect subscale score | ||||
Low | 203 (20.0) | 153 (61.9) | 50 (10.3) | 0 (0.0) |
Medium | 556 (54.8) | 92 (37.3) | 349 (71.8) | 115 (40.9) |
High | 255 (25.2) | 2 (0.8) | 87 (17.9) | 166 (59.1) |
Communication and autonomy subscale score | ||||
Low | 257 (25.4) | 183 (74.1) | 74 (15.2) | 0 (0.0) |
Medium | 500 (49.3) | 64 (25.9) | 364 (74.9) | 72 (25.6) |
High | 257 (25.4) | 0 (0.0) | 48 (9.9) | 209 (74.4) |
Supportive care subscale score | ||||
Low | 248 (24.5) | 194 (78.5) | 48 (9.9) | 0 (0.0) |
Medium | 450 (44.4) | 53 (21.5) | 336 (69.1) | 57 (20.3) |
High | 316 (31.2) | 0 (0.0) | 102 (21.0) | 224 (79.7) |
Maternal complications reported at either follow-up | ||||
No | 873 (86.1) | 204 (82.6) | 417 (85.8) | 252 (89.7) |
Yes | 141 (13.9) | 43 (17.4) | 69 (14.2) | 29 (10.3) |
Screened positive for depression at either follow-up | ||||
No | 845 (83.3) | 186 (75.3) | 410 (84.4) | 249 (88.6) |
Yes | 169 (16.7) | 61 (24.7) | 76 (15.6) | 32 (11.4) |
Adopted family planning method by 10 wk follow-up | ||||
No | 571 (56.3) | 152 (61.5) | 272 (56.0) | 147 (52.3) |
Yes | 443 (43.7) | 95 (38.5) | 214 (44.0) | 134 (47.7) |
Exclusive breastfeeding at 10 wk follow-upa | ||||
No | 151 (18.0) | 40 (20.1) | 75 (18.7) | 36 (15.0) |
Yes | 690 (82.0) | 159 (79.9) | 327 (81.3) | 204 (85.0) |
Newborn complications reported at either follow-up | ||||
No | 687 (67.8) | 148 (59.9) | 336 (69.1) | 203 (72.2) |
Yes | 327 (32.3) | 99 (40.1) | 150 (30.9) | 78 (27.8) |
Returned to a facility for newborn immunizations by 10 wk follow-up | ||||
No | 404 (39.8) | 104 (42.1) | 190 (39.1) | 110 (39.2) |
Yes | 610 (60.2) | 143 (57.9) | 296 (60.9) | 171 (60.9) |
Data are presented as number (percentage). Percentages may not add to 100 because of rounding.
PCMC, person-centered maternity care.
Sudhinaraset. Person-centered maternity care associated with maternal and newborn health. Am J Obstet Gynecol Glob Rep 2021.
Sample size, N=841 (women who completed baseline and 10 weeks follow-up).